key: cord-0737455-b9rcxija
authors: Kervella, Delphine; Jacquemont, Lola; Chapelet-debout, Agnès; Clément deltombe, M.D.; Ville, Simon
title: Minimal Change Disease relapse following SARS-CoV2 mRNA vaccine
date: 2021-05-05
journal: Kidney Int
DOI: 10.1016/j.kint.2021.04.033
sha: 5e49f202f9bba0a77ad25a87a65ed55c4e7970a7
doc_id: 737455
cord_uid: b9rcxija

nan

Although the pathogenesis of minimal change disease (MCD) has not yet been clearly elucidated, immune dysregulation is probable 1 and the risk of relapse after administration of various vaccines (especially meningococcal C conjugate vaccines) has been suggested 2,3 . Here, we report a case of MCD relapse following SARS-CoV2 mRNA vaccine.

The patient was a 34-years old woman with a recent history of nephrotic syndrome diagnosed as minimal change disease (MCD). Steroids allowed complete remission, but she was cortico-dependent as two relapses occurred during steroid tapering ( Figure) . A second-line treatment (rituximab) was thus planned, after vaccination against the SARS-CoV-2 with the BNT162b2 vaccine (Pfizer-BioNTech). Six weeks before the first injection, steroids had been increased (0.5 mg/kg) due to the onset of lowgrade proteinuria, leading to remission. Ten days after first vaccine injection (ongoing steroid dose 0.4 mg/kg) she presented with full-blown relapse (oedema, protein-to-creatinine ratio (PCR) of 2.4 g/g), leading to an increase of steroid dose to 0.5 mg/kg, achieving a decrease in proteinuria (PCR, 1.2 g/g). She received the second injection (27 days after the first one) and few days later proteinuria increased again to a nephrotic range (PCR 3 g/g), leading to a new increase of steroid dose to 1 mg/kg that finally allowed complete remission. Response to the vaccine was satisfying with a positive SARS-Cov2 serology (anti-S protein antibodies assessed by electrochemiluminescence immunoassay (Roche Elecsys®) before second injection at 55.2 U/mL), no other immediate or delayed adverse event occurred following vaccination. This observation suggests that BNT162b2 vaccine could favor MCD relapse, potentially through the stimulation of the immune response and cytokine release it induces. Steroids seem efficient in achieving prompt remission.

Figure. Urine Protein to Creatinine Ratio and steroid dose during follow-up. 1 Diagnosis of idiopathic nephrotic syndrome (minimal change disease diagnosed on a kidney biopsy). 2 First relapse when tapering steroids from 10 to 9 mg, increase of steroid dose to 1 mg/kg (60 mg) leading to remission of NS. 3 Second relapse when tapering steroids from 12.5 to 10 mg, increase of steroid dose to 0.5 mg/kg leading to remission. Covid-19 mRNA vaccine was injected while the patient was treated with 0.4 mg/kg steroids (25 mg, ongoing tapering from last relapse occurring six weeks before first vaccine injection, no proteinuria on urine dipstick test at the time of vaccine injection). 4 Proteinuria after first mRNA Covid-19 vaccine injection, increase of steroid dose from 25 to 30 mg (0.5 mg/kg). 5 Proteinuria increase after second mRNA Covid-19 vaccine injection, increase of steroids to 60 mg (1 mg/kg) leading to remission. iNS idiopathic nephrotic syndrome

Minimal Change Disease

Vaccine-associated kidney diseases: A narrative review of the literature

Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. Please place an "X" next to the following statement to indicate your agreement:_X__ I certify that I have answered every question and have not altered the wording of any of the questions on this form.